Proteomic technologies have emerged as an important addition to the genomic and antibody-based technologies for the diagnosis of cancer. Important technologies include 2-D gel electrophoresis, mass spectrometry, laser capture microdissection, detection of molecular markers of cancer and protein patterns. For clinical applications, the most likely technologies to be used widely are protein biochips. Application of these technologies to various cancers are described. Proteomic technologies have a potential in developing molecular diagnostics and markers for the early detection of cancer. However, information from various diagnostic technologies should be integrated to obtain the optimal information required for clinical management of a patient.
JainK. K.Recent advances in oncoproteomics. Current Opinion in Molecular Therapeutics4, 203–209 (2002).
5.
SinhaP., KohlS., FischerJ.Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis21, 3048–57 (2000).
6.
JainK. K.Application of Laser Capture Microdissection to Proteomics. Methods in Enzymology356, 157–167 (2002).
7.
FungE. T., WrightG. L.Jr., DalmassoE. A.Proteomic strategies for biomarker identification: Progress and challenges. Curr. Opin. Mol. Ther.2, 643–50 (2000).
8.
SimpsonR. J., DorowD. S.Cancer proteomics: From signaling networks to tumor markers. Trends Biotechnol.19, Suppl, S40–8 (2001).
9.
JohnsonP. J.Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J. Gastroenterol. Hepatol14, Suppl, S32–6.
10.
CelisJ. E., WolfH., OstergaardM.Bladder squamous cell carcinoma biomarkers derived from proteomics. Electrophoresis21, 2115–21 (2000).
11.
AlaiyaA. A., FranzenB., HagmanA.Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles. Int. J. Cancer98, 895–9 (2002).
12.
BurchardtM., BurchardtT., ShabsighA.Current concepts in biomarker technology for bladder cancers. Clin. Chem.46, 595–605 (2000).
13.
PetricoinE. F., ArdekaniA. M., HittB. A.Use of proteomic patterns in serum to identify ovarian cancer. Lancet359, 572–577 (2002).
14.
ZhaiG., IskandarM., BarillaK., RomaniukP. J.Characterization of RNA aptamer binding by the Wilms' tumor suppressor protein WT1. Biochemistry40, 2032–40 (2001).
15.
LuftnerD., PossingerK.Nuclear matrix proteins as biomarkers for breast cancer. Expert Rev. Mol. Diagn.2, 23–31 (2002).
16.
PaweletzC. P., TrockB., PennanenM.Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers17, 301–7 (2001).
17.
BrunagelG., VietmeierB. N., BauerA. J.Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res.62, 2437–42 (2002).
18.
NelsonP. S., HanD., RochonY.Comprehensive analyses of prostate gene expression: Convergence of expressed sequence tag databases, transcript profiling and proteomics. Electrophoresis21, 1823–31 (2000).
19.
SimoneN. L., RemaleyA. T., CharboneauL.Sensitive immunoassay of tissue cell proteins procured by laser capture microdissection. Am. J. Pathol.156, 445–52 (2000).
20.
OrnsteinD. K., GillespieJ. W., PaweletzC. P.Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis21, 2235–42 (2000).
21.
Emmert-BuckM. R., GillespieJ. W., PaweletzC. P.An approach to proteomic analysis of human tumors. Mol. Carcinog.27, 158–65 (2000).
22.
VossT., AhornH., HaberlP.Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. Int. J. Cancer91, 180–186 (2001).
23.
BrichoryF. M., MisekD. E., YimA. M.An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl. Acad. Sci. USA98, 9824–9 (2001).
